アシネトバクター感染症(Acinetobacter Infections):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Acinetobacter Infections - Pipeline Review, H2 2014
◆商品コード:GMDHC5685IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:107
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるアシネトバクター感染症(Acinetobacter Infections)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・アシネトバクター感染症(Acinetobacter Infections)の概要
・アシネトバクター感染症(Acinetobacter Infections)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・アシネトバクター感染症(Acinetobacter Infections)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・アシネトバクター感染症(Acinetobacter Infections)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・アシネトバクター感染症(Acinetobacter Infections)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Acinetobacter Infections – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Acinetobacter Infections – Pipeline Review, H2 2014’, provides an overview of the Acinetobacter Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acinetobacter Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acinetobacter Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acinetobacter Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acinetobacter Infections Overview 10
Therapeutics Development 11
Pipeline Products for Acinetobacter Infections – Overview 11
Pipeline Products for Acinetobacter Infections – Comparative Analysis 12
Acinetobacter Infections – Therapeutics under Development by Companies 13
Acinetobacter Infections – Therapeutics under Investigation by Universities/Institutes 16
Acinetobacter Infections – Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Acinetobacter Infections – Products under Development by Companies 19
Acinetobacter Infections – Products under Investigation by Universities/Institutes 21
Acinetobacter Infections – Companies Involved in Therapeutics Development 22
Achaogen Inc. 22
Adenium Biotech ApS 23
AmpliPhi Biosciences Corporation 24
Aridis Pharmaceuticals LLC 25
AstraZeneca PLC 26
ConjuGon, Inc. 27
Evolva SA 28
FOB Synthesis, Inc. 29
LegoChem Biosciences, Inc 30
Melinta Therapeutics, Inc 31
Northern Antibiotics Oy 32
Nosopharm SAS 33
Novan, Inc. 34
Omnia Molecular Ltd. 35
Pfizer Inc. 36
Sarepta Therapeutics, Inc. 37
Sealife PHARMA GMBH 38
Shionogi & Co., Ltd. 39
Synthetic Biologics, Inc. 40
Trana Discovery, Inc. 41
Vaxdyn, S.L. 42
Acinetobacter Infections – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
A-3APO – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AA-139 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Antisense Oligonucleotide for Acinetobacter baumannii Infections – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AR-401 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Biologics for Acinetobacter Baumanii – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BXN-112 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cephalosporin + Beta-Lactamase Inhibitor – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
EV-035 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
FSI-1671 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
FSI-1686 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GN-4474 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
LCB-100200 – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MDN-0057 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MDN-0058 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MDN-0059 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MDN-0060 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
NAB-7061 – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NAB-739 – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
NAB-741 – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
NOSO-95 – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
NVN-4428 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
RX-04 – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
RX-05 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
RXP-873 – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
S-649266 – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
SB-204 – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SLP-0905 – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecule for Acinetobacter baumannii Infections – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Small Molecule for Gram-Negative Nosocomial Infections – Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecules for Gram Negative Bacterial Infections – Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecules for Gram-Negative Bacterial Infections – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections – Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SYN-001 – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
VXD-001 – Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
VXD-003 – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Acinetobacter Infections – Recent Pipeline Updates 100
Acinetobacter Infections – Dormant Projects 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 107
Disclaimer 107

[List of Tables]
Number of Products under Development for Acinetobacter Infections, H2 2014 11
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Acinetobacter Infections - Pipeline by Achaogen Inc., H2 2014 22
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H2 2014 23
Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2014 24
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2014 25
Acinetobacter Infections - Pipeline by AstraZeneca PLC, H2 2014 26
Acinetobacter Infections - Pipeline by ConjuGon, Inc., H2 2014 27
Acinetobacter Infections - Pipeline by Evolva SA, H2 2014 28
Acinetobacter Infections - Pipeline by FOB Synthesis, Inc., H2 2014 29
Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H2 2014 30
Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 31
Acinetobacter Infections - Pipeline by Northern Antibiotics Oy, H2 2014 32
Acinetobacter Infections - Pipeline by Nosopharm SAS, H2 2014 33
Acinetobacter Infections - Pipeline by Novan, Inc., H2 2014 34
Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H2 2014 35
Acinetobacter Infections - Pipeline by Pfizer Inc., H2 2014 36
Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2014 37
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H2 2014 38
Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H2 2014 39
Acinetobacter Infections - Pipeline by Synthetic Biologics, Inc., H2 2014 40
Acinetobacter Infections - Pipeline by Trana Discovery, Inc., H2 2014 41
Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H2 2014 42
Assessment by Monotherapy Products, H2 2014 43
Assessment by Combination Products, H2 2014 44
Number of Products by Stage and Target, H2 2014 46
Number of Products by Stage and Mechanism of Action, H2 2014 48
Number of Products by Stage and Route of Administration, H2 2014 50
Number of Products by Stage and Molecule Type, H2 2014 52
Acinetobacter Infections Therapeutics - Recent Pipeline Updates, H2 2014 100
Acinetobacter Infections - Dormant Projects, H2 2014 105

[List of Figures]
Number of Products under Development for Acinetobacter Infections, H2 2014 11
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Early Stage Products, H2 2014 18
Assessment by Monotherapy Products, H2 2014 43
Number of Products by Top 10 Targets, H2 2014 45
Number of Products by Stage and Top 10 Targets, H2 2014 46
Number of Products by Top 10 Mechanism of Actions, H2 2014 47
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 48
Number of Products by Top 10 Routes of Administration, H2 2014 49
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 50
Number of Products by Top 10 Molecule Types, H2 2014 51
Number of Products by Stage and Top 10 Molecule Types, H2 2014 52

【掲載企業】

Achaogen Inc.
Adenium Biotech ApS
AmpliPhi Biosciences Corporation
Aridis Pharmaceuticals LLC
AstraZeneca PLC
ConjuGon, Inc.
Evolva SA
FOB Synthesis, Inc.
LegoChem Biosciences, Inc
Melinta Therapeutics, Inc
Northern Antibiotics Oy
Nosopharm SAS
Novan, Inc.
Omnia Molecular Ltd.
Pfizer Inc.
Sarepta Therapeutics, Inc.
Sealife PHARMA GMBH
Shionogi & Co., Ltd.
Synthetic Biologics, Inc.
Trana Discovery, Inc.
Vaxdyn, S.L.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アシネトバクター感染症(Acinetobacter Infections):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆